Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial 

Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy  

However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses  

Findings from two studies show high rates of complete remissions in patients with Bacillus Calmette-Guérin unresponsive high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer 

Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade 

Practice changing results of event-free survival and overall survival are reported from the NIAGARA study

The first results from two phase III studies of Ra-223 and ¹⁷⁷Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC 

According to results from several phase I trials, this precision oncology strategy also offers manageable safety

Final overall survival data from the CONTACT-02 study are negative, but a survival advantage was observed with the novel combination in patients with liver or bone metastasis